Drug Profile


Alternative Names: Recombinant human decorin

Latest Information Update: 25 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Burnham Institute
  • Developer Telios Pharmaceuticals
  • Class Antihyperglycaemics; Hepatoprotectants
  • Mechanism of Action Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Diabetic nephropathies; Inflammation; Post-surgical adhesions; Pulmonary fibrosis; Spinal cord injuries

Most Recent Events

  • 02 Feb 2000 A preclinical study has been added to the pharmacodynamics section
  • 01 Dec 1998 Preclinical development for Post-surgical adhesions in USA (Unknown route)
  • 25 Nov 1998 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top